Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14844574 | 0.82 | P2RX7 (0.49) | HDAC1HDAC8HDAC6ITGAVGSK3B | |
| SCHEMBL158296 | 0.80 | HDAC1 (0.39) | HDAC1HDAC8HDAC6BAZ2BPLK1 | |
| SCHEMBL13631423 | 0.79 | ITGAV (0.50) | HDAC1HDAC8HDAC6ITGAVCNR1 | |
| SCHEMBL23331083 | 0.79 | HDAC1 (0.40) | HDAC1HDAC8HDAC6ITGAVGSK3B | |
| SCHEMBL13631425 | 0.79 | NPC1 (0.43) | HDAC1HDAC8HDAC6ITGAVCNR1 | |
| SCHEMBL21423708 | 0.78 | FBP1 (0.49) | HDAC1HDAC8HDAC6BAZ2BHPGD | |
| SCHEMBL749645 | 0.78 | HDAC1 (0.38) | HDAC1HDAC8HDAC6BAZ2BCNR1 | |
| SCHEMBL4480406 | 0.78 | HDAC1 (0.38) | HDAC1HDAC8HDAC6BAZ2BCNR1 | |
| SCHEMBL18236189 | 0.78 | HDAC1 (0.45) | HDAC1HDAC8HDAC6BAZ2BCNR1 | |
| SCHEMBL9792694 | 0.78 | ITGAV (0.46) | HDAC1HDAC8HDAC6ITGAVCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430006-B1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-26 | — | — | EP | claimed |
| EP-2430012-B1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | claimed |
| EP-2430012-A1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-21 | — | — | EP | claimed |
| WO-2010130945-A1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-11-18 | — | — | WO | claimed |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023102140-A1 | TMPRSS2 INHIBITORS AND METHODS OF USE | TOPSPIN THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220386614-A1 | OXADIAZOLINE COMPOUND OR SALTS THEREOF, AGRICULTURAL AND HORTICULTURAL BACTERICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | NIHON NOHYAKU CO., LTD. (JP) | 2022-12-08 | — | — | US | disclosed |
| WO-2021132577-A1 | ACYLSULFAMIDE COMPOUND AND PHARMACEUTICAL USE THEREFOR | 日本たばこ産業株式会社 | 2021-07-01 | — | — | WO | disclosed |
| EP-3725798-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-10-21 | — | — | EP | disclosed |
| EP-3233834-B1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE AND 3,4-DIHYDRO-2H-PYRROL-5-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-13 | — | — | EP | disclosed |
| US-10329558-B2 | Method for producing compound containing heterocycle | THE UNIVERSITY OF TOKYO (JP) | 2019-06-25 | — | — | US | disclosed |
| WO-2019114666-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-06-20 | — | — | WO | disclosed |
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| EP-2430012-A1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130945-A1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130945-A1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130944-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-11-18 | — | — | WO | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | HDAC1 1777/4885HDAC8 282/4885HDAC6 384/4885 |
| US-20220386614-A1 | OXADIAZOLINE COMPOUND OR SALTS THEREOF, AGRICULTURAL AND HORTICULTURAL BACTERICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | BROX, CYP51A1, TBCD | HDAC1 460/4885HDAC8 1453/4885HDAC6 788/4885 |
| US-10329558-B2 | Method for producing compound containing heterocycle | VIP, DNPEP, PREP | HDAC1 1589/4885HDAC8 2045/4885HDAC6 3147/4885 |
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | EPOR, ACAD9, CBR1 | HDAC1 710/4885HDAC8 64/4885HDAC6 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.